Dec 23, 2021 |
Oncocyte Switches Gears on Transplant Test Commercialization, Plans to Launch LDT Next Year
|
PDF
|
Dec 09, 2021 |
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer
|
PDF
|
Dec 08, 2021 |
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China
|
PDF
|
Dec 06, 2021 |
Oncocyte Corporation Hosting Business Update Call
|
PDF
|
Dec 02, 2021 |
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021
|
PDF
|
Nov 09, 2021 |
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
|
PDF
|
Nov 04, 2021 |
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
|
PDF
|
Oct 26, 2021 |
Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th
|
PDF
|
Oct 07, 2021 |
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
|
PDF
|
Sep 30, 2021 |
Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer
|
PDF
|